CLEO Diagnostics Ltd (AU:COV) has released an update.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
CLEO Diagnostics Ltd has announced the commencement of U.S. clinical trials for its novel ovarian cancer diagnostic blood test, with seven sites selected across various states, including Texas and New York. These trials, pivotal for obtaining FDA approval, are set to begin in mid-August 2024 and will be complemented by a concurrent trial in Australia. The company aims to address the critical need for early detection of ovarian cancer with its test, which distinguishes malignant from benign growths.
For further insights into AU:COV stock, check out TipRanks’ Stock Analysis page.